Therapeutic area
Acute migraine
Acute episodic migraine: the 2025 ACP network meta-analysis and guideline
In 21 head-to-head and 165 placebo-controlled trials, the 2025 ACP network meta-analysis found larger effects on pain outcomes for triptans than for NSAIDs (high certainty) or acetaminophen (low certainty), often with a higher adverse-event risk.
Parenteral therapy for migraine in the emergency department: what the 2025 update found
The 2025 American Headache Society update added 26 randomized trials and rates intravenous prochlorperazine and greater occipital nerve block level A, must offer, and intravenous hydromorphone level A, must not offer.